Chemotherapy for metastatic melanoma: time for a change?
about
Interferon alpha for the adjuvant treatment of cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaIsolated limb perfusion for malignant melanoma: systematic review on effectiveness and safetyMelanoma brain metastases: an unmet challenge in the era of active therapyMicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD)Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatinGypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation.Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biologyStrategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.Patterns of expression of DNA repair genes and relapse from melanoma.Jacaranone induces apoptosis in melanoma cells via ROS-mediated downregulation of Akt and p38 MAPK activation and displays antitumor activity in vivo.BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity.Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk.Design, synthesis, and biological evaluation of N-acetyl-S-(p-chlorophenylcarbamoyl)cysteine and its analogs as a novel class of anticancer agents.Current concepts of metastasis in melanoma.Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapyPhase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanomaNew horizons in melanoma treatment: targeting molecular pathways.Melanoma proliferation and chemoresistance controlled by the DEK oncogeneMolecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapySuppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosisAugmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancementTargeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanomaCXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2.The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK.Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLsFibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.A growing family: adding mutated Erbb4 as a novel cancer targetClinical features of malignant melanoma of the finger and therapeutic efficacies of different treatmentsABT-737 synergizes with Bortezomib to kill melanoma cells.Effects of a novel Nodal-targeting monoclonal antibody in melanomaMitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survivalDepletion of T lymphocytes is correlated with response to temozolomide in melanoma patients.Novel inhibitors in the treatment of metastatic melanoma.Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell linesPara-Phenylenediamine Induces Apoptotic Death of Melanoma Cells and Reduces Melanoma Tumour Growth in Mice
P2860
Q24201908-628676A0-4897-4C01-8E65-33FF389DC26EQ24235257-C04ADD82-8CB8-4569-9D00-1C61DEB2CE1EQ24633360-5CA9A310-935A-4608-BDFF-CDF18D1DBD76Q26995622-F717CC77-4696-4014-89CD-B9D7E371BC03Q28280193-AE0D60E0-9223-4F7A-80C1-8D9205718E52Q28539631-B73509C1-E3C4-4BEE-A168-0E086C79B498Q28547966-5D89A698-4F2D-42BC-BEBC-D30EBD72257FQ33613608-A2F9CC2E-269C-4660-B64F-6C7E30EECFA9Q33656600-4FE2DAFF-6E52-415A-A0CE-E87FF660099BQ33757127-E834066A-2F96-420A-9E6B-D28B33631871Q34273603-8B4694A2-E4BA-486A-A48D-B28473D839DAQ34305683-E5107B86-A324-4AE3-A63D-D322936ED52EQ34354569-83F14690-1518-4A81-8FAB-97BD3F2E8C66Q34365708-E3CAE9E0-FB7B-408F-868F-3570FFEC8FBFQ34520444-41646109-0D13-4DB5-B925-A30308F0A10CQ34610427-67598203-99DC-4997-972E-3E852E505220Q34823783-98E0D59D-A4AE-47C0-8719-D01C397CCB25Q34887442-6B7AE814-59D2-427E-B39D-E95C3836A663Q34986188-ADA41BD8-DB85-40FB-B563-A7A1A5B8708BQ34997265-3CAC0685-7B1B-4A6E-84EC-4F8AED61B7C5Q35118157-9A7A28E9-F6F8-4363-BFA4-446C0938DC38Q35230726-2044DC4B-1040-4F2F-A343-C5AEB1834DD7Q35382043-04F127F7-203A-4526-9887-CE3C910B13A6Q35434352-533D72CA-47D0-4C27-97EB-7ED94837D4A7Q35583851-9AAE753F-3E0A-4C8D-9118-6EFE36EEE2E5Q35584186-DCCC1786-F406-40E5-90F5-45B5833DC643Q35749307-6877380E-E78B-4381-83A4-7F3B23742524Q35871624-505F6CD8-6894-4FD6-9BE9-FD0C4128622CQ35877576-B51FC892-910F-40F6-AE03-4135C013BC44Q36028423-E8F2D51E-60C1-4028-B270-9E3FF8825192Q36059811-B366067B-8956-426D-AF4A-41C411551145Q36062442-A20071C0-3330-4D0B-BC72-C2DA396D23D1Q36126814-5DA01F5C-54D9-4631-B233-05D3086D4537Q36425600-5AA24D5B-99A9-4E9A-9889-70B6A32CD698Q36544020-9CB69A0C-E063-470B-956C-14EBD128A9D1Q36654285-02913EA7-E6AA-4516-9ED2-778F0278FE80Q36694942-C7157905-2E5D-46A4-B4A4-FDD0F6D680D7Q36817132-975DF89F-2DEB-4C3E-9963-5CCF3069F298Q36940730-7E8E23DB-1008-4BC4-A83E-F11F8D580B50Q36949093-9129B78E-95D3-4BB4-B33F-0918885599C7
P2860
Chemotherapy for metastatic melanoma: time for a change?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Chemotherapy for metastatic melanoma: time for a change?
@ast
Chemotherapy for metastatic melanoma: time for a change?
@en
type
label
Chemotherapy for metastatic melanoma: time for a change?
@ast
Chemotherapy for metastatic melanoma: time for a change?
@en
prefLabel
Chemotherapy for metastatic melanoma: time for a change?
@ast
Chemotherapy for metastatic melanoma: time for a change?
@en
P2093
P356
P1433
P1476
Chemotherapy for metastatic melanoma: time for a change?
@en
P2093
Helen J Gogas
John M Kirkwood
Vernon K Sondak
P304
P356
10.1002/CNCR.22427
P407
P577
2007-02-01T00:00:00Z